DA 9805 / Dong-A - LARVOL DELTA

DA-9805, a Herbal Mixture, Restores Motor Manifestations in 6-Hydroxydopamine-induced Parkinson's Disease Mouse Model by Regulating Striatal Dopamine and Acetylcholine Levels. (PubMed, Front Pharmacol) - "We also found that the level of striatal acetylcholine (Ach) has the moderate negative correlation with motor functions and TH expression in the SNpc. This study indicates that DA-9805 restores motor dysfunctions by normalizing the increased levels of striatal Ach via modulating DA transmission and ChAT expressions as well as its neuroprotective effects."

Journal • Preclinical • CNS Disorders • Movement Disorders • Parkinson's Disease

DA-9805 protects dopaminergic neurons from endoplasmic reticulum stress and inflammation. (PubMed, Biomed Pharmacother) - "Pre-treatment with DA-9805 (1 μg/ml) attenuated upregulation of glucose-regulated protein 78 (GRP78), C/EBP homologous protein (CHOP) and cleaved caspase-3 in SH-SY5Y neuroblastoma cells treated with thapsigargin (1 µg/ml) or tunicamycin (2 µg/ml). Oral administration of DA-9805 (10 or 30 mg/kg/day for 3 days before LPS injection) prevented loss of dopaminergic neurons and activation of microglia and astrocytes in the substantia nigra in LPS-injected mouse models. Taken together, these results indicate that DA-9805 can effectively prevent ER stress and neuroinflammation, suggesting that DA-9805 is a multitargeting and disease-modifying therapeutic candidate for PD."

Journal • CNS Disorders • Immunology • Inflammation • Movement Disorders • Neuroblastoma • Oncology • Parkinson's Disease • Solid Tumor • CASP3 • HSPA5 • IL1B • IL6 • TNFA

Dong-A ST posts robust profit in 2019 (Korea Biomedical Review) - "The company said that it has completed its U.S. phase 2a clinical trial for DA-9805, a Parkinson's disease treatment...Also, the company plans to complete its local phase 1 clinical trial for DA-5207, a weekly patch-type dementia treatment, in the first half of this year. At the same time, it has received approval to conduct a phase 1 clinical trial for the drug candidate in India. It said DA-9801, a diabetic neuropathy treatment licensed out to NeuroBo, will be tested soon in a phase 3 trial in the U.S."

New P3 trial • Trial completion • Trial status

Safety and Efficacy of DA-9805 for Parkinson's Disease (clinicaltrials.gov) - P2a; N=60; Completed; Sponsor: Dong-A ST Co., Ltd.; Active, not recruiting ➔ Completed

Clinical • Trial completion

Protective effects of DA-9805 on dopaminergic neurons against 6-hydroxydopamine-induced neurotoxicity in the models of Parkinson's disease. (PubMed, Biomed Pharmacother) - "Furthermore, DA-9805 prevented 6-OHDA-induced movement impairment, as well as a decrease of dopaminergic neurons and dopamine transmission in rodents. Taken together, these results suggest that the mixed herbal formula DA-9805 may be a pharmaceutical agent for preventing or improving PD."

Journal

Triple herbal extract DA-9805 exerts a neuroprotective effect via amelioration of mitochondrial damage in experimental models of Parkinson's disease. (PubMed, Sci Rep) - "These results demonstrate that the triple herbal extract DA-9805 showed neuroprotective effects via alleviating mitochondria damage in experimental models of PD. We propose that DA-9805 may be a suitable candidate for disease-modifying therapeutics for PD."

Journal

Dong-A ST posts robust Q1 profit (Korea Biomedical Review) - "'The R&D for the company's major pipelines is proceeding smoothly,' Dong-A ST said in a news release. 'They include...DA-9805, a Parkinson's disease treatment candidate...'"

Trial status

TRIPLE HERBAL EXTRACT DA-9805 EXERTS A NEUROPROTECTIVE EFFECT IN EXPERIMENTAL MODELS OF PARKINSON’S DISEASE (ADPD 2019) - "These results demonstrate that the triple herbal extract DA-9805 showed neuroprotective effects in experimental models of PD. We propose that DA-9805 may be a suitable candidate for disease-modifying therapeutics against PD."